1-10 of 10
bendamustine
Close
Sort by
Journal Articles

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas

Clinical Trials & Observations
Nora Liebers, Johannes Duell, Donnacha Fitzgerald, Andrea Kerkhoff, Daniel Noerenberg, Eva Kaebisch, Fabian Acker, Stephan Fuhrmann, Corinna Leng, Manfred Welslau, Jens Chemnitz, Jan-Moritz Middeke, Thomas Weber, Udo Holtick, Ralf Trappe, Roald Pfannes, Ruediger Liersch, Christian Spoer, Stefan Fuxius, Niklas Gebauer, Léandra Caillé, Thomas Geer, Christian Koenecke, Ulrich Keller, Rainer Claus, Dimitrios Mougiakakos, Stephanie Mayer, Andreas Huettmann, Christiane Pott, Arne Trummer, Gerald Wulf, Uta Brunnberg, Lars Bullinger, Georg Hess, Carsten Mueller-Tidow, Bertram Glass, Georg Lenz, Peter Dreger, Sascha Dietrich
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2707–2716.
https://doi.org/10.1182/bloodadvances.2020004155
Published: 2021
Includes: Supplemental data
Journal Articles

Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma

Clinical Trials & Observations
Diego Villa, Laurie H. Sehn, Kerry J. Savage, Cynthia L. Toze, Kevin Song, Wendie D. den Brok, Ciara L. Freeman, David W. Scott, Alina S. Gerrie
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3486–3494.
https://doi.org/10.1182/bloodadvances.2020002068
Published: 2020
Includes: Supplemental data
Journal Articles

Bendamustine-induced immune hemolytic anemia: a case report and systematic review of the literature

Clinical Trials & Observations
Maverick Chan, William K. Silverstein, Anna Nikonova, Katerina Pavenski, Lisa K. Hicks
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1756–1759.
https://doi.org/10.1182/bloodadvances.2020001726
Published: 2020
Journal Articles

The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites

Clinical Trials & Observations
Anthony Mato, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Charles M. Farber, Matthew S. Davids, Arlene S. Swern, Kristen Sullivan, E. Dawn Flick, Sarah M. Gressett Ussery, Mecide Gharibo, Pavel Kiselev, Jeff P. Sharman
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1407–1418.
https://doi.org/10.1182/bloodadvances.2019001145
Published: 2020
Includes: Supplemental data
Journal Articles

Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

Clinical Trials & Observations
Reid W. Merryman, Natasha Edwin, Robert Redd, Jad Bsat, Matthew Chase, Ann LaCasce, Arnold Freedman, Caron Jacobson, David Fisher, Samuel Ng, Jennifer Crombie, Austin Kim, Oreofe Odejide, Matthew S. Davids, Jennifer R. Brown, Heather Jacene, Amanda Cashen, Nancy L. Bartlett, Neha Mehta-Shah, Armin Ghobadi, Brad Kahl, Robin Joyce, Philippe Armand, Eric Jacobsen
Journal: Blood Advances
Blood Adv (2020) 4 (5): 858–867.
https://doi.org/10.1182/bloodadvances.2019001355
Published: 2020
Includes: Supplemental data
Journal Articles

Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma

Clinical Trials & Observations
Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Manuela Zanni, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Francesca Ricci, Carmelo Carlo-Stella
Journal: Blood Advances
Blood Adv (2020) 4 (1): 136–140.
https://doi.org/10.1182/bloodadvances.2019000984
Published: 2020
Includes: Supplemental data
Journal Articles

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3132–3135.
https://doi.org/10.1182/bloodadvances.2019000526
Published: 2019
Journal Articles

Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma

Clinical Trials & Observations
M. Picardi, R. Della Pepa, C. Giordano, N. Pugliese, C. Mortaruolo, F. Trastulli, M. G. Rascato, I. Cappuccio, M. Raimondo, M. Memoli, M. Monteverde, M. Mascolo, F. Pane
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1546–1552.
https://doi.org/10.1182/bloodadvances.2019000123
Published: 2019
Journal Articles

Early progression of disease as a predictor of survival in chronic lymphocytic leukemia

Clinical Trials & Observations
Inhye E. Ahn, Charles M. Farber, Matthew S. Davids, David L. Grinblatt, Neil E. Kay, Nicole Lamanna, Anthony Mato, Chadi Nabhan, Pavel Kiselev, Arlene S. Swern, E. Dawn Flick, Kristen Sullivan, Jeff P. Sharman, Christopher R. Flowers
Journal: Blood Advances
Blood Adv (2017) 1 (25): 2433–2443.
https://doi.org/10.1182/bloodadvances.2017011262
Published: 2017
Includes: Supplemental data
Journal Articles

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Journal: Blood Advances
Blood Adv (2016) 1 (2): 122–131.
https://doi.org/10.1182/bloodadvances.2016000976
Published: 2016
Includes: Supplemental data